NCT04151563 2023-12-19
CheckMate 79X
Bristol-Myers Squibb
Phase 1/2 Withdrawn
Clinical Trials
10 trialsNCT05284214 2023-09-15
SALIENT
Partner Therapeutics, Inc.
Phase 2 Withdrawn
NCT02854488 2022-03-31
Yervoy Pregnancy Surveillance Study
Bristol-Myers Squibb
Withdrawn
NCT04607200 2022-01-11
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
Agenus Inc.
Phase 2 Withdrawn
NCT04060407 2021-06-01
CINDI
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2 Withdrawn
NCT04495010 2021-03-19
CheckMate 7UA
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT03048136 2018-04-17
CheckMate 955
Bristol-Myers Squibb
Phase 3 Withdrawn
NCT00732186 2016-02-17
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT00357461 2013-05-15
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT00803374 2011-11-21
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
Bristol-Myers Squibb
Phase 1 Withdrawn